Sonnet BioTherapeutics Holdings, Inc. reported its financial results for the third quarter of fiscal year 2025, revealing a net loss of $3.8 million for the three months ended June 30, 2025, compared to a loss of $3.5 million for the same period in 2024. For the nine months ended June 30, 2025, the company recorded a net loss of $10.4 million, significantly higher than the $4.3 million loss reported in the prior year. The increase in losses is attributed to rising operating expenses, particularly in research and development, which totaled $6.2 million for the nine-month period, up from $4.5 million in the previous year.
The company did not generate any collaboration revenue during the three months ended June 30, 2025, while it recognized $1 million in collaboration revenue for the nine months ended June 30, 2025, primarily from its agreement with Alkem Laboratories for the development of SON-080. This marks a substantial decrease from the $18,626 in collaboration revenue reported for the same period in 2024. Operating expenses for the quarter increased to $3.8 million, up from $3.5 million in the prior year, driven by higher research and development costs associated with ongoing clinical trials.
In terms of strategic developments, Sonnet has made significant progress in its clinical programs, particularly with SON-1010, which is being evaluated in multiple trials for solid tumors. The company has expanded its Phase 1 clinical study to include a new cohort assessing the combination of SON-1010 with trabectedin, and it is also conducting a Phase 1b/2a trial in collaboration with Roche for the use of SON-1010 in combination with atezolizumab. The company’s total assets decreased to $2.1 million as of June 30, 2025, down from $2.8 million at the end of the previous fiscal year, primarily due to increased liabilities.
Operationally, Sonnet's cash position improved slightly, with cash at $321,297 as of June 30, 2025, compared to $149,456 at the end of the previous quarter. However, the company continues to face substantial liquidity challenges, raising concerns about its ability to sustain operations without additional financing. In July 2025, Sonnet raised $10.5 million through the exercise of warrants and completed a private placement of convertible notes and preferred stock, which is expected to fund operations into early 2026. The company anticipates needing further capital to support ongoing clinical trials and operational expenses.
Looking ahead, Sonnet BioTherapeutics remains focused on advancing its clinical pipeline while navigating the challenges of funding and operational sustainability. The company has indicated that it will continue to seek additional financing through equity offerings and collaborations to support its growth strategy. The upcoming milestones for its clinical programs, particularly for SON-1010 and SON-080, will be critical in determining the company's future trajectory and potential for revenue generation.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics is a clinical-stage biotechnology company developing innovative biologic medicines, primarily targeting oncology and neuropathy. Its proprietary FHAB platform enhances cytokine delivery and tumor targeting. The company’s pipeline includes cytokine-based therapies for cancer, chemotherapy-induced peripheral neuropathy, and diabetic peripheral neuropathy, leveraging modular, long-acting constructs to improve efficacy and safety in immune modulation and nerve regeneration.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.